SCHEMBL5860010

SCHEMBL5860010

CCOC(=O)C(Cc1ccccc1Cl)(NC(C)=O)C(=O)OCC

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.67
RECQL P46063 1/20 0.67
MAPK1 P28482 1/20 0.52
PKM P14618 2/20 0.51
KDM4E B2RXH2 1/20 0.51
ATM Q13315 2/20 0.50
THRB P10828 2/20 0.50
HTT P42858 2/20 0.49
HPGD P15428 1/20 0.48
MAPT P10636 3/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
TAAR1 Q96RJ0 2/20 0.45
LMNA P02545 1/20 0.45
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7786981 0.94 ALDH1A1 (0.62) ALDH1A1RECQLMAPK1PKMKDM4E
SCHEMBL29168265 0.90 ALDH1A1 (0.60) ALDH1A1RECQLMAPK1PKMKDM4E
SCHEMBL1686141 0.84 ALDH1A1 (0.67) ALDH1A1RECQLMAPK1PKMKDM4E
SCHEMBL4705070 0.84 ALDH1A1 (0.67) ALDH1A1RECQLMAPK1PKMKDM4E
SCHEMBL16001113 0.84 ALDH1A1 (0.67) ALDH1A1RECQLMAPK1PKMKDM4E
SCHEMBL23004849 0.84 ALDH1A1 (0.67) ALDH1A1RECQLMAPK1PKMKDM4E
SCHEMBL9849152 0.84 ALDH1A1 (0.67) ALDH1A1RECQLMAPK1PKMKDM4E
SCHEMBL10624673 0.83 ALDH1A1 (0.65) ALDH1A1RECQLMAPK1PKMKDM4E
SCHEMBL22425298 0.82 ALDH1A1 (0.54) ALDH1A1RECQLMAPK1PKMKDM4E
SCHEMBL27394284 0.82 ALDH1A1 (0.64) ALDH1A1RECQLMAPK1PKMKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020169203-A1 Ion channel modulating agents NEUROSEARCH A/S (DK) 2002-11-14 US claimed
EP-1140784-A2 ION CHANNEL MODULATING AGENTS NEUROSEARCH A/S (DK) 2001-10-10 EP claimed
WO-2000037422-A2 ION CHANNEL MODULATING AGENTS NEUROSEARCH A/S (DK) 2000-06-29 WO claimed
US-7012146-B2 Ion channel modulating agents POSEIDON PHARMACEUTICALS A/S (DK) 2006-03-14 US disclosed
US-20020169203-A1 Ion channel modulating agents NEUROSEARCH A/S (DK) 2002-11-14 US disclosed
EP-1140784-A2 ION CHANNEL MODULATING AGENTS NEUROSEARCH A/S (DK) 2001-10-10 EP disclosed
WO-2000037422-A2 ION CHANNEL MODULATING AGENTS NEUROSEARCH A/S (DK) 2000-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020169203-A1 Ion channel modulating agents KCNN3, KCNN1, KCNN2 ALDH1A1 4482/4885RECQL 2506/4885MAPK1 1449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.